Belzutifan Plus Pembrolizumab Cuts Kidney Cancer Recurrence by 28% After Surgery in Phase 3 Trial
About one in five patients with kidney cancer who receives the standard post-surgical immunotherapy pembrolizumab will still relapse. That failure rate has driven researchers to search for combination approaches - ways to pair the checkpoint inhibitor's immune activation with a second mechanism that targets different drivers of tumor survival.
Data presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium offer the first phase 3 evidence that such a combination can work in the adjuvant setting - after surgery, when no detectable cancer remains but the statistical risk of recurrence is high. The trial, called LITESPARK-022, tested pembrolizumab plus belzutifan against pembrolizumab plus placebo in 1,841 patients with clear cell renal cell carcinoma who had undergone surgery and had elevated recurrence risk.
What the Numbers Show
At a median follow-up of 28.4 months, the combination arm showed a 28% reduction in recurrence compared to the control arm. In absolute terms, 81% of patients in the belzutifan plus pembrolizumab group remained cancer-free, versus 74% in the pembrolizumab plus placebo group. The side effect profile was consistent with previously reported data for both drugs individually.
Overall survival data have not yet matured - the follow-up period is too short to determine whether the improvement in disease-free survival translates into a survival benefit. That data point is the one oncologists and regulators will ultimately weigh most heavily, and it will require more time and additional events.
Why Belzutifan
Belzutifan is a HIF-2-alpha inhibitor. In clear cell renal cell carcinoma, HIF-2-alpha - a protein that regulates cellular response to oxygen levels - is constitutively overactive, driving tumor growth through angiogenesis and metabolic reprogramming. Blocking it attacks a pathway that is central to ccRCC biology in a way that differs mechanistically from immunotherapy.
The scientific foundation for belzutifan traces to research by Dr. William G. Kaelin, Jr. of Dana-Farber Cancer Institute, who shared the 2019 Nobel Prize in Physiology or Medicine for discoveries on how cells sense and adapt to oxygen - work that directly led to the development of HIF-2-alpha inhibitors as a drug class.
"A significant percentage of patients with high risk kidney cancer will recur within five years after surgery because microscopic cancer cells can remain undetected," said Dr. Toni Choueiri, director of the Lank Center for Genitourinary Cancer at Dana-Farber and the study's lead investigator. "We need new therapies that can work together to better prevent the cancer from coming back."
Context and Caveats
The trial enrolled patients specifically categorized as high risk for recurrence after surgery - a group defined by tumor stage, grade, and other pathological features. Whether the combination offers benefit in patients with lower recurrence risk was not tested and cannot be inferred from these results.
Previous work by Choueiri's group established pembrolizumab alone as standard of care in high-risk adjuvant ccRCC. LITESPARK-022 builds directly on that foundation, testing whether adding a second mechanism improves on an already-effective baseline. The 28% relative reduction in recurrence is meaningful, but the absolute difference - seven percentage points at 28 months - will need to be weighed against any added toxicity and cost as the data mature.
The trial is sponsored by Merck Sharp and Dohme, a subsidiary of Merck and Co., the manufacturer of both pembrolizumab (Keytruda) and belzutifan (Welireg).